A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
Sarina A Piha-PaulEcaterina E DumbravaBinoj C NairWendy XiongLi XuRosa MostorinoVivek SubbiahNizar TannirSiqing FuAung NaingFilip JankuDaniel D KarpShreyaskumar PatelNajat C DawDavid HongFunda Meric-BernstamRalph ZinnerPublished in: OncoTargets and therapy (2021)
Dose level 6 (crizotinib 200 mg twice daily and pazopanib 600 mg daily) was the most tolerable dosing of the combination and can be used in future studies. We also observed moderate clinical activity in patients with advanced solid tumors that had received numerous prior therapies.
Keyphrases
- advanced non small cell lung cancer
- physical activity
- clinical trial
- study protocol
- cell death
- metastatic renal cell carcinoma
- epidermal growth factor receptor
- endothelial cells
- dna damage
- phase iii
- vascular endothelial growth factor
- high intensity
- tyrosine kinase
- randomized controlled trial
- reactive oxygen species
- case control